Leslie T. Busby, MD

Research Reports

Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival

10/21/2020

Aimee Ginsburg , PharmD, BCPS;

J. Russell Hoverman , MD, PhD;

Angela Hsieh , PharmD, BCOP;

Kartik Konduri , MD;

Leslie T. Busby , MD;

Lalan Wilfong , MD;

John M. Burke , MD;

Marcus A. Neubauer , MD;

Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...

...

10/21/2020

Journal of Clinical Pathways

Letters to the Editor

Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars

10/20/2021

Aimee Ginsburg , PharmD, BCPS;

Kaci Dominguez , PharmD;

Leslie T. Busby , MD;

Josh Howell , PharmD, BCOP;

Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.

Aimee Ginsburg, PharmD, BCPS,...

10/20/2021

Journal of Clinical Pathways